Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of <i>DPYD</i> Genotype-Guided Therapy with Fluoropyrimidines: An Observational Study
Fluoropyrimidines (FPs) are commonly prescribed in many cancer streams. The EMA and FDA-approved drug labels for FPs recommend genotyping the <i>DPYD</i>*2A (rs3918290), *13 (rs55886062), *HapB3 (rs56038477), alleles, and <i>DPYD</i> rs67376798 before treatment starts. We imp...
Bewaard in:
Hoofdauteurs: | , , , , , , , , , , |
---|---|
Formaat: | Boek |
Gepubliceerd in: |
MDPI AG,
2024-07-01T00:00:00Z.
|
Onderwerpen: | |
Online toegang: | Connect to this object online. |
Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|
Internet
Connect to this object online.3rd Floor Main Library
Plaatsingsnummer: |
A1234.567 |
---|---|
Kopie 1 | Beschikbaar |